Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.0002 USD | -99.67% | 0.00% | -99.67% |
02/05 | North American Morning Briefing : Stock Futures -2- | DJ |
25/04 | North American Morning Briefing : More Tech -2- | DJ |
Valuation
Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 |
---|---|---|---|---|---|
Capitalization 1 | 413.3 | 130.3 | 558.4 | 324.5 | 176.5 |
Enterprise Value (EV) 1 | 277.7 | 72.07 | 531.3 | 312.4 | 179.7 |
P/E ratio | -4.67 x | -1.52 x | -5.1 x | -2.63 x | -1.23 x |
Yield | - | - | - | - | - |
Capitalization / Revenue | - | - | - | - | - |
EV / Revenue | - | - | - | - | - |
EV / EBITDA | -4.94 x | -0.85 x | -5.91 x | -2.76 x | -1.69 x |
EV / FCF | -8.65 x | -1.54 x | -13.1 x | -5.11 x | -2.94 x |
FCF Yield | -11.6% | -65% | -7.61% | -19.6% | -34% |
Price to Book | 3.02 x | 2.17 x | 18.8 x | 37.5 x | -35.8 x |
Nbr of stocks (in thousands) | 1,588 | 1,604 | 2,309 | 2,673 | 5,481 |
Reference price 2 | 260.2 | 81.20 | 241.8 | 121.4 | 32.20 |
Announcement Date | 15/02/19 | 14/02/20 | 09/03/21 | 24/03/22 | 16/03/23 |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
---|---|---|---|---|---|---|
Net sales | - | - | - | - | - | - |
EBITDA 1 | -26.7 | -56.17 | -84.59 | -89.86 | -113.2 | -106.4 |
EBIT 1 | -27.53 | -58.1 | -86.36 | -91.89 | -115.4 | -108.5 |
Operating Margin | - | - | - | - | - | - |
Earnings before Tax (EBT) 1 | -28.05 | -56.95 | -85.28 | -93.26 | -121.7 | -113.6 |
Net income 1 | -28.05 | -56.95 | -85.47 | -93.67 | -122.2 | -114.5 |
Net margin | - | - | - | - | - | - |
EPS 2 | -182.0 | -55.67 | -53.37 | -47.45 | -46.18 | -26.28 |
Free Cash Flow 1 | -15.63 | -32.12 | -46.85 | -40.41 | -61.1 | -61.02 |
FCF margin | - | - | - | - | - | - |
FCF Conversion (EBITDA) | - | - | - | - | - | - |
FCF Conversion (Net income) | - | - | - | - | - | - |
Dividend per Share | - | - | - | - | - | - |
Announcement Date | 05/03/18 | 15/02/19 | 14/02/20 | 09/03/21 | 24/03/22 | 16/03/23 |
Income Statement Evolution (Quarterly data)
Fiscal Period: December | 2021 Q2 | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 |
---|---|---|---|---|---|---|---|---|---|
Net sales 1 | - | - | - | - | - | - | - | - | - |
EBITDA | - | - | - | - | - | - | - | - | - |
EBIT 1 | -27.66 | -32.71 | -27.56 | -28.74 | -29.59 | -29.05 | -21.09 | -24.9 | -19.57 |
Operating Margin | - | - | - | - | - | - | - | - | - |
Earnings before Tax (EBT) 1 | -31.54 | -33.57 | -28.56 | -29.74 | -30.4 | -30.46 | -23 | -25.2 | -20.87 |
Net income 1 | -31.6 | -33.73 | -28.65 | -29.86 | -30.56 | -30.56 | -23.54 | -25.34 | -21.1 |
Net margin | - | - | - | - | - | - | - | - | - |
EPS 2 | -11.80 | -12.60 | -10.80 | -11.20 | -8.000 | -5.600 | -3.400 | -4.600 | -3.780 |
Dividend per Share | - | - | - | - | - | - | - | - | - |
Announcement Date | 29/07/21 | 28/10/21 | 24/03/22 | 12/05/22 | 11/08/22 | 14/11/22 | 16/03/23 | 15/05/23 | 14/08/23 |
Balance Sheet Analysis
Fiscal Period: December | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
---|---|---|---|---|---|---|
Net Debt 1 | - | - | - | - | - | 3.2 |
Net Cash position 1 | 28.3 | 136 | 58.2 | 27.1 | 12.1 | - |
Leverage (Debt/EBITDA) | - | - | - | - | - | -0.0301 x |
Free Cash Flow 1 | -15.6 | -32.1 | -46.9 | -40.4 | -61.1 | -61 |
ROE (net income / shareholders' equity) | -160% | -68.5% | -86.7% | -207% | -624% | -6,233% |
ROA (Net income/ Total Assets) | -55.2% | -35.7% | -43% | -63.3% | -80.8% | -89% |
Assets 1 | 50.82 | 159.7 | 198.6 | 148.1 | 151.2 | 128.7 |
Book Value Per Share 2 | -282.0 | 86.10 | 37.40 | 12.80 | 3.240 | -0.9000 |
Cash Flow per Share 2 | 197.0 | 58.50 | 48.40 | 29.00 | 25.50 | 8.650 |
Capex 1 | 1.74 | 5.46 | 3.03 | 1.32 | 1.52 | 0.62 |
Capex / Sales | - | - | - | - | - | - |
Announcement Date | 05/03/18 | 15/02/19 | 14/02/20 | 09/03/21 | 24/03/22 | 16/03/23 |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
1st Jan change | Capi. | |
---|---|---|
-99.67% | 1.14M | |
+16.55% | 122B | |
+20.22% | 115B | |
+21.22% | 26.64B | |
-23.39% | 19.91B | |
-17.47% | 16.32B | |
-45.95% | 15.52B | |
-18.95% | 15.49B | |
+62.07% | 14.83B | |
+2.85% | 13.67B |
- Stock Market
- Equities
- EVLO Stock
- Financials Evelo Biosciences, Inc.